Drug intelligence / Profile preview

HRS-1301

Development stage: Phase 2
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HRS-1301 is an investigational small molecule drug developed for the treatment of hyperlipidemia. It is classified as a class 1 chemical drug and is currently in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects and those with elevated LDL-C. The precise mechanism of action has not been disclosed publicly. Preclinical studies suggest that HRS-1301 can effectively improve hyperlipidemia, but no similar drugs are approved or marketed globally at this time[5][7][1].

Targets

PCSK9 (Proprotein convertase subtilisin/kexin type 9)

Beyond the preview

Go deeper on HRS-1301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS-1301.

Explore the full profile